Authors
Mateo, JCarreira, S
Sandhu, S
Miranda, S
Mossop, H
Perez-Lopez, R
Nava Rodrigues, D
Robinson, D
Omlin, A
Tunariu, N
Boysen, G
Porta, N
Flohr, P
Gillman, A
Figueiredo, I
Paulding, C
Seed, G
Jain, S
Ralph, C
Protheroe, A
Hussain, S
Jones, R
Elliott, Tony
McGovern, U
Bianchini, D
Goodall, J
Zafeiriou, Z
Williamson, C
Ferraldeschi, R
Riisnaes, R
Ebbs, B
Fowler, G
Roda, D
Yuan, W
Wu, Y
Cao, X
Brough, R
Pemberton, H
A'Hern, R
Swain, A
Kunju, L
Eeles, R
Attard, G
Lord, C
Ashworth, A
Rubin, M
Knudsen, K
Feng, F
Chinnaiyan, A
Hall, E
de Bono, J
Affiliation
Institute of Cancer Research, LondonIssue Date
2015-10-29
Metadata
Show full item recordAbstract
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.Citation
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 2015, 373 (18):1697-708 N Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1506859PubMed ID
26510020Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1506859
Scopus Count
Collections
Related articles
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.
- Authors: de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M
- Issue date: 2020 May 28
- Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
- Authors: Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES
- Issue date: 2024 Oct 1
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
- Authors: Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J, PROfound Trial Investigators
- Issue date: 2020 Dec 10
- Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
- Authors: Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES
- Issue date: 2019 Oct
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
- Authors: Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS
- Issue date: 2020 Jan